|Bid||15.00 x N/A|
|Ask||15.50 x N/A|
|Day's range||15.00 - 16.00|
|52-week range||4.65 - 51.00|
|Beta (5Y monthly)||0.91|
|PE ratio (TTM)||N/A|
|Earnings date||11 Mar 2021 - 12 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
LONDON, October 07, 2021--Kanabo, one of Europe’s fastest-growing medical cannabis R&D companies that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, has signed a partnership agreement with the Medocann Pharma Ltd. to develop new products that will target specific medical conditions. The deal gives Kanabo exclusive distribution rights to the co-developed products into the growing German and UK cannabis markets.
LONDON, September 22, 2021--Kanabo’s VapePod, the world’s first medical grade vaporiser is now available to UK customers on Handpicked CBD, to use with three new proprietary formulas: Reload, Relax and Repair.
The big shareholder groups in Kanabo Group Plc ( LON:KNB ) have power over the company. Insiders often own a large...